Updated 2025 Market Reports Released: Trends, Forecasts to 2034 – Early Purchase Your Competitive Edge Today!

How has the extended-release drugs market size evolved in recent years?

The market size for extended-release drugs has seen significant expansion in the past years. A rise from $63.11 billion in 2024 to $70.28 billion in 2025, with a compound annual growth rate (CAGR) of 11.4% is expected. Factors contributing to this growth from the historical period include enhancements in patient compliance, an increase in chronic illnesses, better efficiency, strategic patent protection, and the use of biodegradable implants.

What are the predictions for the extended-release drugs market size in the coming years?

The market for extended-release medications is projected to see a swift expansion in the coming years, surging to a value of $113.05 billion by 2029, with a compound annual growth rate of 12.6%. Factors influencing this growth during the projected period include the emergence of customised medicine, patient-specified drug development, an increased prevalence of diseases linked to modern lifestyles, repurposed drugs, and worldwide availability of extended-release treatments. Forecasts also point towards significant trends including pharmaceutical developments, enhancements in drug delivery systems, nanotechnology advances, the application of 3D printing in drug creation, AI involvement, and environmental sustainability.

Get your extended-release drugs market report here!

https://www.thebusinessresearchcompany.com/report/extended-release-drugs-global-market-report

What key factors are fueling the growth of the extended-release drugs market?

The extended-release drug market is predicted to expand due to the growing prevalence of chronic diseases. Chronic diseases are characterized as those lasting a year or more, requiring ongoing medical attention, and may limit daily activities. Heart disease, cancer, obesity, and diabetes are among these health conditions. Extended-release drug delivery systems aim to ensure a steady amount of medication in the body for an extended time, thus maintaining a constant therapeutic effect and preventing the variability in drug levels associated with instant-release medications. For example, the US-based National Library of Medicine’s National Center for Biotechnology Information (NCBI) projected that by 2050, the number of people aged 50 and older with at least one chronic disease will increase by 99.5% to 142.66 million. Hence, the rise in chronic disease prevalence is prompting the growth of the extended-release drug market.

How is the global extended-release drugs market divided into key segments?

The extended-release drugs market covered in this report is segmented –

1) By Type: Sustained Release Drug, Controlled Release Drug

2) By Mode: Over-The-Counter, Prescription

3) By Distribution Channel: Hospital Pharmacies, Retail Pharmacies, Mail Order Pharmacies, Drug Stores

Subsegments:

1) By Sustained Release Drug: Matrix Systems, Coating Systems

2) By Controlled Release Drug: Osmotic Systems, Microencapsulation Systems, Targeted Delivery Systems

Get your free sample now – explore exclusive market insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12675&type=smp

Who are the key firms paving the way for growth in the extended-release drugs market?

Major companies operating in the extended-release drugs market include Pfizer Inc., AbbVie Inc., Novartis AG, Sanofi SA, GlaxoSmithKline PLC, AstraZeneca Plc, Gilead Sciences Inc., Boehringer Ingelheim International GmbH, Viatris Inc., Teva Pharmaceuticals Inc., Eastman Chemical Company, Catalent Pharma Solutions Inc., Sun Pharmaceutical Industries Limited, Purdue Pharma LP, Amneal Pharmaceuticals Inc., Endo Pharmaceuticals Inc., Mallinckrodt LLC, Allergan plc, Hisamitsu Pharmaceutical Co. Inc., Janssen Pharmaceuticals Inc., Noven Pharmaceuticals Inc., Mayne Pharma Group Ltd., Neos Therapeutics Inc., Ardena Holding NV, UPM Pharmaceuticals Inc., Oakwood Laboratories LLC, Roxane Laboratories Inc., Lavipharm Laboratories Inc., Watson Pharmaceuticals Inc.

Which trends are expected to transform the extended-release drugs market?

In the extended-release drug market, product innovation is emerging as a significant trend. To maintain their market standing, major firms involved in this market are inventing new products. For example, in July 2022, Zydus Pharmaceuticals (USA) Inc., an American generic pharmaceutical company, initiated the launch of Topiramate extended-release capsules aimed at epilepsy. The company had earlier received approval from the US Food and Drug Administration (USFDA) to market Topiramate extended-release capsules, USP 25 mg, 50 mg, and 100 mg. They are the first enterprise in the US to secure final approval and roll out Topiramate extended-release capsules. The authorization for these extended-release tablets was granted for those experiencing partial onset or primary generalized tonic-clinic seizures.

Unlock exclusive market insights – purchase your research report now for a swift delivery!

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12675

What regions are contributing significantly to the growth of the extended-release drugs market?

North America was the largest region in the extended-release drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the extended-release drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Browse Through More Similar Reports By The Business Research Company:

Controlled Release Fertilizer Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/controlled-release-fertilizer-global-market-report

Drugs of Abuse (DOA) Testing Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-of-abuse-doa-testing-global-market-report

Drugs For Benign Prostatic hypertrophy Global Market Report 2024

https://www.thebusinessresearchcompany.com/report/drugs-for-benign-prostatic-hypertrophy-global-market-report

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Contact us at:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at [email protected]

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model

Found this article helpful? Share it on: